Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

EGFR signalling breast cancer cdk4/6 inhibitors chemotherapy resistance oestrogen receptor

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
16 Dec 2021
Historique:
received: 10 10 2021
revised: 05 12 2021
accepted: 11 12 2021
entrez: 24 12 2021
pubmed: 25 12 2021
medline: 25 12 2021
Statut: epublish

Résumé

While endocrine therapy is highly effective for the treatment of oestrogen receptor-α (ERα)-positive breast cancer, a significant number of patients will eventually experience disease progression and develop treatment-resistant, metastatic cancer. The majority of resistant tumours remain dependent on ERα-action, with activating

Identifiants

pubmed: 34944934
pii: cancers13246314
doi: 10.3390/cancers13246314
pmc: PMC8699146
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Cancer Research UK
ID : 12011
Pays : United Kingdom
Organisme : Dutch Research Council
ID : 91716401
Pays : Netherlands
Organisme : Oncode Institute
ID : Zwart

Références

Breast Cancer. 2020 May;27(3):415-425
pubmed: 31823286
Cell Cycle. 2006 Aug;5(16):1799-807
pubmed: 16929185
Nat Rev Cancer. 2018 Jun;18(6):377-388
pubmed: 29662238
Cancer Res. 2016 Apr 15;76(8):2301-13
pubmed: 27020857
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Eur J Cancer. 2018 Sep;101:123-133
pubmed: 30053671
Trends Cancer. 2020 Oct;6(10):838-857
pubmed: 32482536
Semin Oncol. 2017 Dec;44(6):385-394
pubmed: 29935900
Semin Cancer Biol. 2017 Jun;44:72-82
pubmed: 28344165
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Nat Commun. 2017 Jan 06;8:13897
pubmed: 28059068
J Biol Chem. 2000 Jul 7;275(27):20867-72
pubmed: 10787412
J Biol Chem. 2003 Jul 18;278(29):27278-86
pubmed: 12736255
Exp Mol Med. 2020 Apr;52(4):569-581
pubmed: 32300189
Oncogene. 2020 Jul;39(29):5165-5176
pubmed: 32541838
Science. 1991 Jun 28;252(5014):1848-51
pubmed: 2063198
Cell. 2010 Apr 2;141(1):69-80
pubmed: 20371346
Cancer. 2019 Nov 1;125(21):3714-3728
pubmed: 31318440
PLoS Med. 2016 Dec 27;13(12):e1002201
pubmed: 28027327
Cancer Res. 2018 Jun 15;78(12):3267-3279
pubmed: 29555874
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
Mol Cell Biol. 1997 Aug;17(8):4644-53
pubmed: 9234721
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Oncogene. 2001 Dec 13;20(57):8203-14
pubmed: 11781836
J Adv Pract Oncol. 2021 Jan-Feb;12(1):100-107
pubmed: 33552665
Mol Endocrinol. 1996 Nov;10(11):1388-98
pubmed: 8923465
Genome Biol. 2014;15(12):550
pubmed: 25516281
Trends Cell Biol. 2014 Jan;24(1):26-34
pubmed: 24295852
Nat Genet. 2013 Dec;45(12):1446-51
pubmed: 24185510
World J Biol Chem. 2015 Aug 26;6(3):231-9
pubmed: 26322178
J Clin Oncol. 2016 Sep 1;34(25):2961-8
pubmed: 27269946
Cancer Sci. 2019 Feb;110(2):474-480
pubmed: 30575231
Oncotarget. 2018 Feb 26;9(21):15658-15672
pubmed: 29644000
J Hematol Oncol. 2020 May 1;13(1):41
pubmed: 32357912
Nat Commun. 2021 Jul 16;12(1):4360
pubmed: 34272384
J Cancer. 2017 Jul 5;8(11):2004-2009
pubmed: 28819400
Clin Cancer Res. 2016 Dec 1;22(23):5696-5705
pubmed: 27542767
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
Cell Cycle. 2012 Jul 15;11(14):2747-55
pubmed: 22751436
ESMO Open. 2018 Aug 20;3(5):e000368
pubmed: 30167331
Cell Chem Biol. 2019 Aug 15;26(8):1067-1080.e8
pubmed: 31178407
Cancer Cell. 2018 Feb 12;33(2):173-186.e5
pubmed: 29438694
Nat Cancer. 2021 Jun;2(6):658-671
pubmed: 34712959
Clin Breast Cancer. 2019 Dec;19(6):392-398
pubmed: 31358432
Oncogene. 2017 Apr 20;36(16):2286-2296
pubmed: 27748765
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Front Endocrinol (Lausanne). 2019 May 24;10:245
pubmed: 31178825
Lancet Oncol. 2021 Feb;22(2):159-160
pubmed: 33460573
Thorac Cancer. 2020 Sep;11(9):2389-2397
pubmed: 32677256
Cancer Discov. 2017 Mar;7(3):277-287
pubmed: 27986707
Elife. 2016 Feb 02;5:
pubmed: 26836308
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61
pubmed: 23180760
Biochemistry. 2002 Apr 2;41(13):4209-17
pubmed: 11914066
Eat Behav. 2015 Aug;18:160-78
pubmed: 26112228
Mol Cancer Ther. 2016 Jul;15(7):1702-12
pubmed: 27196756
J Biol Chem. 1998 Oct 23;273(43):28371-7
pubmed: 9774463
J Proteome Res. 2017 Feb 3;16(2):728-737
pubmed: 28107008
Horm Cancer. 2018 Aug;9(4):215-228
pubmed: 29736566
J Cancer Metastasis Treat. 2019;5:
pubmed: 31106278
Bioinformatics. 2017 Jun 26;33(21):3489-3491
pubmed: 28655153
J Biol Chem. 2012 Aug 17;287(34):29075-87
pubmed: 22733811
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncogene. 2019 May;38(20):3886-3902
pubmed: 30692638
Cancer Cell. 2020 Mar 16;37(3):340-353.e6
pubmed: 32109375

Auteurs

Isabel Mayayo-Peralta (I)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.

Beatrice Faggion (B)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.

Liesbeth Hoekman (L)

Proteomics Facility, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.

Ben Morris (B)

Division of Molecular Carcinogenesis and Robotics and Screening Centre, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.

Cor Lieftink (C)

Division of Molecular Carcinogenesis and Robotics and Screening Centre, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.

Isabella Goldsbrough (I)

Department of Surgery & Cancer, Imperial College London, London SW7 2BX, UK.

Lakjaya Buluwela (L)

Department of Surgery & Cancer, Imperial College London, London SW7 2BX, UK.

Joseph C Siefert (JC)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.

Harm Post (H)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands.

Maarten Altelaar (M)

Proteomics Facility, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands.

Roderick Beijersbergen (R)

Division of Molecular Carcinogenesis and Robotics and Screening Centre, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.

Simak Ali (S)

Department of Surgery & Cancer, Imperial College London, London SW7 2BX, UK.

Wilbert Zwart (W)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, 5612 AZ Eindhoven, The Netherlands.

Stefan Prekovic (S)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.

Classifications MeSH